🔎 Trials Near Me

መነሻ › አኩት ማይሎይድ ሊውኬሚያ › ኮነቲከት › Bridgeport

በBridgeport፣ CT ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ 12 ጥናቶች በBridgeport እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Stony Brook University Medical Center, Stony Brook · 18 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT05564390

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
  • Stony Brook University Medical Center, Stony Brook · 18 ማይል ርቀት
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Stony Brook University Medical Center, Stony Brook · 18 ማይል ርቀት
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Stony Brook University Medical Center, Stony Brook · 18 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Stony Brook University Medical Center, Stony Brook · 18 ማይል ርቀት
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Stony Brook University Medical Center, Stony Brook · 18 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Stony Brook University Medical Center, Stony Brook · 18 ማይል ርቀት
6 Months – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT04293562

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Stony Brook University Medical Center, Stony Brook · 18 ማይል ርቀት
እስከ እድሜ 22 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04726241

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Stony Brook Cancer Center, Stony Brook · 18 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT06001788

Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Stony Brook Cancer Center, Stony Brook · 18 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT06297551

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Stony Brook University Hospital, Stony Brook · 18 ማይል ርቀት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Stony Brook University Hospital, Stony Brook · 18 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ማርች 2026 · NCT05735184

በሌሎች ከተሞች ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ጥናቶች

በBridgeport ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።